Product Specifications:
Item# 1041: Recombinant HIV-1 IIIB Glycoprotein gp120 (CHO)
Concentration: See vial
Diluent: PBS
Purity: >95%
Stabilizer: None
Preservative: None
Storage: -75°C
Physical State: Frozen
Liquid Stability: At least 6 months at -75°C.
Applications: In-Vitro Diagnostics, CD4 Binding, T-Cell Activation.
Description: Full length Recombinant HIV-1 IIIB gp120 glycoprotein produced in the CHO Expression System.
Purification: This protein is purified by immunoaffinity chromatography to >95% purity as determined by SDS-PAGE, reduced.
Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and human serum polyclonal antibodies in ELISA and Western ELISA.
Biological Activity: This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti-gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4-), in vitro, as measured by RNA synthesis during G0 to G1 transition phase of antigen-binding competent cells.
Application and Instructions for use
Recommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. ELISA and Western ELISA require 10-100ng protein depending on the nature and affinity of the detection reagent. Human serum polyclonal antibodies yield titers of 1:1000 or greater at 100ng of solid phase protein under standard ELISA conditions.
Item#: 1041-P Peroxidase-Conjugated rgp120 HIV-1 IIIB
Application: Human diagnostics, CD4 binding, Drug screening, Human T-cell CD4 studies.
Safety Study of rgp120/HIV-1IIIB Vaccine
Recent evidence suggests that gp120 is the HIV-1 protein with the greatest potential as a vaccine against HIV-1 infection. The gp120 envelope protein may be produced by recombinant DNA technology, and studies have shown that the vaccine is capable of eliciting neutralizing antibody activity in both rodents and nonhuman primate species.
Official Study Title: A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)
Disease: HIV Infections
Treatment: Biological: rgp120/HIV-1IIIB and Biological: rgp120/HIV-1MN
ORIGINAL DESIGN: Twenty-eight subjects will be randomized to receive 100 or 300 mcg rgp120/HIV-1IIIB vaccine (gp120 vaccine) or matching placebo. For each dose level, 10 subjects will receive vaccine and four subjects will receive matching placebo. Injections are given intramuscularly at 0, 4, and 32 weeks. Each subject receiving treatment at the lower dose level must be monitored for unacceptable toxicity for at least 2 weeks following the initial immunization before his or her second dose is administered and before treatment at the higher dose level begins. Subjects are followed for at least 12 months.
AMENDED 11/17/93: Selected subjects from VEU 006 or VEU 006 Rollover study will receive two injections of MN rgp120 vaccine, administered 28 days apart beginning 10-16 months after their last injection. Eight additional clinic visits will be required. Subjects are followed for at least 6 months.
CHO- expressed HIV-1IIIB rgp120 (2.5 μg) and biotinylated cyclic V2-TH023 peptide (1 μg and 5 μg) were incubated with RPMI8866 cells
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
最近遇到了实验上的大问题，就是用一步法做RNA的荧光定量PCR时，发现低浓度的做不出来，而DNA是可以的，想请问各位在一步法PCR中有没有什么高见，就是逆转录的Buffer有没有什么需要注意的地方！就是在逆转录酶的最适Buffer和Taq酶的最适Buffer中寻找一个最适的Buffer！
ResponseofskeletalmuscleRNApolymerasesIandIItotumourgrowth
BiochimicaetBiophysicaActa(BBA)-GeneStructureandExpression,Volume950,Issue3,7September1988,Pages296-302
GeorgeA.J.Goodlad,CatherineM.Clark
或者有高手知道怎么测也行
请规范发贴，求助贴请在标题前加【求助】，谢谢您的合作。——by草根
我是新手。我要开始做实验了，但一开始就碰到了个很大的问题。
我想买个能利用哺乳动物细胞RNA聚合酶将DNA转录成RNA的的质粒，向好几家公司打了电话，但都没有我想要的东西。
没有这个东西，我的实验就只能是蓝图了。哪位战友有办法的，能不能帮帮我？
不胜感激。
B、酶细胞产能细胞内（外）起作用消化酶细胞外起作用B错误；
C、酶同需要适条件同胃蛋白酶与胰蛋白酶所需PH同C错误；
D、葡萄糖细胞质基质解丙酮酸需要酶催化D确．
故选：D．
暂无品牌问答
